Antibiotics and the Gut Microbiome
A study recently published in Nature Communications (30 June) has shown that even small...
read more
Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).
Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.
Status current
Associated Fund Rainbow Seed Fund
Sector Medical / Biotechnology
Website www.procartabio.com

A study recently published in Nature Communications (30 June) has shown that even small...
read more
Clara Franch de la Cal will be representing Procarta Biosystems at the 17th International Conference...
read more
The BEAM Alliance is working “to improve the regulatory, investment, and commercial environments in...
read more
Evidence is mounting for the risk we are placing ourselves at through overuse of...
read more
Evidence is mounting for the risk we are placing ourselves at through overuse of...
read more
Chaired by Jim O’Neil this third paper on antimicrobial resistance published in May 2015...
read more